{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:13:54Z","timestamp":1792844034450,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HAV Vaccines Ltd","award":["HCR00870"],"award-info":[{"award-number":["HCR00870"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widespread seroprevalence of neutralising antibodies. We have constructed a replication deficient simian adenovirus-vectored vaccine (ChAdOx2) expressing 4 genes from the Mycobacterium avium subspecies paratuberculosis (AhpC, Gsd, p12 and mpa). Safety and T-cell immunogenicity results of the first clinical use of the ChAdOx2 vector are presented here. The trial was conducted using a \u2018three-plus-three\u2019 dose escalation study design. We demonstrate the vaccine is safe, well tolerated and immunogenic.<\/jats:p>","DOI":"10.3390\/vaccines7020040","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T11:37:40Z","timestamp":1557920260000},"page":"40","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5330-0240","authenticated-orcid":false,"given":"Pedro M.","family":"Folegatti","sequence":"first","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-0032","authenticated-orcid":false,"given":"Duncan","family":"Bellamy","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Powlson","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-7839","authenticated-orcid":false,"given":"Nick J.","family":"Edwards","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F.","family":"Mair","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-4045","authenticated-orcid":false,"given":"Georgina","family":"Bowyer","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poulton","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia H.","family":"Mitton","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Green","sequence":"additional","affiliation":[{"name":"Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Berrie","sequence":"additional","affiliation":[{"name":"Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Lawrie","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V.S.","family":"Hill","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-9836","authenticated-orcid":false,"given":"Katie J.","family":"Ewer","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hermon-Taylor","sequence":"additional","affiliation":[{"name":"Department of Nutritional Sciences, Faculty of Life Sciences &amp; Medicine, Franklin Wilkins Building, King\u2019s College London, London SE1 9NH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","first-page":"83","article-title":"Recombinant viruses as tools to induce protective cellular immunity against infectious diseases","volume":"7","author":"Rocha","year":"2004","journal-title":"Int. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/biol.1995.0025","article-title":"Recombinant adenoviruses as vaccines","volume":"23","author":"Perricaudet","year":"1995","journal-title":"Biologicals"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1086\/587993","article-title":"Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag\/pol\/nef vaccine in healthy adults","volume":"46","author":"Priddy","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/aid.2008.0212","article-title":"Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults","volume":"25","author":"Harro","year":"2009","journal-title":"AIDS Res. Human Retrovirus."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00144-09","article-title":"Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults","volume":"16","author":"Harro","year":"2009","journal-title":"Clin. Vacc. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1086\/650299","article-title":"A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)","volume":"201","author":"Kibuuka","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1086\/655468","article-title":"AIDS clinical trials group 5197: A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein","volume":"202","author":"Schooley","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jaoko, W., Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E.M., Graham, B.S., Koup, R.A., and Bailer, R.T. (2010). Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012873"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Peiperl, L., Morgan, C., Moodie, Z., Li, H., Russell, N., Graham, B.S., Tomaras, G.D., De Rosa, S.C., and McElrath, M.J. (2010). Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054). PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013579"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Churchyard, G.J., Morgan, C., Adams, E., Hural, J., Graham, B.S., Moodie, Z., Grove, D., Gray, G., Bekker, L.G., and McElrath, M.J. (2011). A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021225"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Keefer, M.C., Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., Cashin-Cox, M., Naarding, M., Clark, L., and Fernandez, N. (2012). A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041936"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","article-title":"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study","volume":"14","author":"Gray","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Omosa-Manyonyi, G., Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., and Voss, G. (2015). A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125954"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2013.228","article-title":"Circumventing antivector immunity: Potential use of nonhuman adenoviral vectors","volume":"25","author":"Podgorski","year":"2014","journal-title":"Human Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1586\/14760584.2015.1077122","article-title":"Adenovirus-vectored Ebola vaccines","volume":"14","author":"Gilbert","year":"2015","journal-title":"Expert Rev. Vacc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1128\/CMR.7.3.328","article-title":"Paratuberculosis","volume":"7","author":"Cocito","year":"1994","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1017\/S095026881500076X","article-title":"The zoonotic potential of Mycobacterium avium ssp. paratuberculosis: A systematic review and meta-analyses of the evidence","volume":"143","author":"Waddell","year":"2015","journal-title":"Epidemiol. Infect."},{"key":"ref_24","first-page":"1068","article-title":"Chronic Interstitial Enteritis","volume":"2","author":"Dalziel","year":"1913","journal-title":"Brit. Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijmm.2014.07.006","article-title":"Facts, myths and hypotheses on the zoonotic nature of Mycobacterium avium subspecies paratuberculosis","volume":"304","author":"Atreya","year":"2014","journal-title":"Int. J. Med. Microbiol. IJMM"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/AEM.71.4.2130-2139.2005","article-title":"Mycobacterium avium subsp. paratuberculosis in the catchment area and water of the River Taff in South Wales, United Kingdom, and its potential relationship to clustering of Crohn\u2019s disease cases in the city of Cardiff","volume":"71","author":"Pickup","year":"2005","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/AEM.68.5.2428-2435.2002","article-title":"Incidence of Mycobacterium paratuberculosis in bulk raw and commercially pasteurized cows\u2019 milk from approved dairy processing establishments in the United Kingdom","volume":"68","author":"Grant","year":"2002","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOG.0000000000000364","article-title":"Etiopathogenesis of inflammatory bowel disease: Today and tomorrow","volume":"33","year":"2017","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/1040841X.2011.638273","article-title":"Crohn\u2019s disease and the mycobacterioses: A quarter century later. Causation or simple association?","volume":"38","author":"Chiodini","year":"2012","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1473-3099(07)70211-6","article-title":"Mycobacterium avium subspecies paratuberculosis and Crohn\u2019s disease: A systematic review and meta-analysis","volume":"7","author":"Feller","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00592-016-0909-2","article-title":"Type 1 diabetes in Sardinia: Facts and hypotheses in the context of worldwide epidemiological data","volume":"54","author":"Songini","year":"2017","journal-title":"Acta Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fneur.2017.00216","article-title":"Conflicting Role of Mycobacterium Species in Multiple Sclerosis","volume":"8","author":"Cossu","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bull, T.J., Gilbert, S.C., Sridhar, S., Linedale, R., Dierkes, N., Sidi-Boumedine, K., and Hermon-Taylor, J. (2007). A novel multi-antigen virally vectored vaccine against Mycobacterium avium subspecies paratuberculosis. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0001229"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/fvl-2016-0070","article-title":"Simian adenoviruses as vaccine vectors","volume":"11","author":"Morris","year":"2016","journal-title":"Fut. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/jvi.70.7.4805-4810.1996","article-title":"Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli","volume":"70","author":"Chartier","year":"1996","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Dicks, M.D., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V., and Cottingham, M.G. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sheehan, S., Harris, S.A., Satti, I., Hokey, D.A., Dheenadhayalan, V., Stockdale, L., Manjaly Thomas, Z.-R., Minhinnick, A., Wilkie, M., and Vermaak, S. (2015). A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141687"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jix086","article-title":"Higher T-Cell Responses Induced by DNA\/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial","volume":"215","author":"Janes","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mensah, V.A., Gueye, A., Ndiaye, M., Edwards, N.J., Wright, D., Anagnostou, N.A., Syll, M., Ndaw, A., Abiola, A., and Bliss, C. (2016). Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167951"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.vaccine.2016.03.104","article-title":"MERS-CoV vaccine candidates in development: The current landscape","volume":"34","author":"Modjarrad","year":"2016","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector","volume":"205","author":"Duncan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1128\/JVI.01749-06","article-title":"Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity","volume":"80","author":"Thorner","year":"2006","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI60202","article-title":"Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine","volume":"122","author":"Frahm","year":"2012","journal-title":"J. Clin. Invest."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: Mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/2\/40\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:52:16Z","timestamp":1760187136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/7\/2\/40"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["vaccines7020040"],"URL":"https:\/\/doi.org\/10.3390\/vaccines7020040","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]}}}